NCT02266940View on ClinicalTrials.gov

Relative Bioavailability DS-1971a Suspension and Tablets and Food Effect on DS-1971a Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Healthy
Interventions
DRUG

DS-1971a suspension

DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.

DRUG

DS-1971a tablet

A 200 mg DS 1971a tablet for oral administration

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research Ltd, London

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY